Vera Therapeutics, Inc.
Clinical trials sponsored by Vera Therapeutics, Inc., explained in plain language.
-
New hope for kidney disease: drug aims to slow damage in IgA nephropathy
Disease control OngoingThis phase 3 study tests a drug called atacicept in 376 adults with IgA nephropathy, a kidney disease that can lead to kidney failure. The goal is to see if atacicept can reduce protein in the urine and slow the decline in kidney function compared to a placebo. Participants must …
Phase: PHASE3 • Sponsor: Vera Therapeutics, Inc. • Aim: Disease control
Last updated May 01, 2026 15:57 UTC
-
New monthly shot aims to control kidney disease
Disease control OngoingThis study tests a drug called atacicept given every 4 weeks to 90 adults with IgA nephropathy, a kidney disease. The goal is to see if it lowers harmful protein levels in the blood and is safe. Participants receive either weekly or monthly doses to find the best schedule.
Phase: PHASE2 • Sponsor: Vera Therapeutics, Inc. • Aim: Disease control
Last updated Apr 30, 2026 15:51 UTC